| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015891 |
| Receipt No. | R000017676 |
| Official scientific title of the study | Study to evaluate the clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF) |
| Date of disclosure of the study information | 2014/12/10 |
| Last modified on | 2017/04/27 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Study to evaluate the clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF) | |
| Title of the study (Brief title) | Study to evaluate the clinical effectiveness of I-HDF | |
| Region |
|
|
| Condition | ||
| Condition | Chronic Kidney Failure | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the clinical condition and quality of life (QOL) of I-HDF compared with HD. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | SF-36 ver2
Clinical condition (VAS scale) |
| Key secondary outcomes | Vital signs (blood pressure, pulse)
Number of treatments by medical staff Blood test Dose of erythropoietin-stimulating agent Solute removal ability |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | |||
| No. of arms | 2 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | HD therapy (for 3 months) --> I-HDF therapy (for 3 months) --> HD therapy (for 3 months) | ||
| Interventions/Control_2 | I-HDF therapy (for 3 months) --> HD therapy (for 3 months) --> I-HDF therapy (for 3 months) | ||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Hemodialysis patient who on-line HDF therapy is possible, and can give written informed consent
- 18 years and over - Hemodialysis for more than 6 months |
|||
| Key exclusion criteria | 1) Patients with severe cardiovascular disease (NYHA class 3 or 4), hepatic failure, respiratory failure, or malignant tumor
2) 8% or more of the rate of weight gain 3) Patients who are judged ineligible by the attending physician. |
|||
| Target sample size | 70 | |||
| Research contact person | |
| Name of lead principal investigator | Michio Mineshima |
| Organization | Tokyo Women's Medical University |
| Division name | Department of Clinical Engineering |
| Address | 8-1, Kawada-cho, Shinjuku-ku, Tokyo |
| TEL | 03-3353-8111 |
| mmine@twmu.ac.jp | |
| Public contact | |
| Name of contact person | Ryoichi Sakiyama |
| Organization | Tokyo Women's Medical University |
| Division name | Department of Clinical Engineering |
| Address | 8-1, Kawada-cho, Shinjuku-ku, Tokyo |
| TEL | 03-3353-8111 |
| Homepage URL | |
| sakiyama@twmu.ac.jp | |
| Sponsor | |
| Institute | I-HDF Multicenter Study Group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | JMS Co., Ltd.
Asahi Kasei Medical Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 常磐病院(福島県)
名港共立クリニック(愛知県) 偕行会城西病院(愛知県) 偕行会セントラルクリニック(愛知県) 鴨島川島クリニック(徳島県) 鳴門川島クリニック(徳島県) 中島土谷クリニック(広島県) 大町土谷クリニック(広島県) 新古賀クリニック(福岡県) 古賀病院21(福岡県) 伊都クリニック(福岡県) たかみや医院(熊本県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017676 |